18.-20. April 2013
3rd ITLT Essen 2013: Interdisciplinary Treatment of Liver Tumors Essen/Germany |
|
Pharmacokinetic characteristics of the new treatment combination of sorafenib and resminostat, a novel histone deacetylase (HDAC) inhibitor, in patients with advanced hepatocellular carcinoma (HCC): the SHELTER study |
8.-9. November 2012
2nd Cancer Epigenetics Conference, Boston/USA, oral presentations 8 Nov. 2012, 11:35 am (EST) and 12:00 noon (EST) |
|
"Resminostat: Targeting Drug Tolerance by Epigenetic Regulation of Histone Acetylation" |
14.-16. Sept. 2012
ILCA Konferenz: 6. Jahrestagung der International Liver Cancer Association (ILCA) in Berlin (Vortrag, 16. Sept. 2012, 10:30 Uhr MESZ) |
|
Efficacy, Tolerability and Pharmacokinetics of the Oral Histone Deacetylase Inhibitor Resminostat in Patients with Advanced Hepatocellular Carcinoma: Clinical Data from the Phase 2 Shelter Study |
27.-30. Juni 2012
EMSO GI Konferenz: 14th World Congress on Gastrointestinal Cancer of the European Society for Medical Oncology in Barcelona, Spanien |
|
Dose Escalation of the HDAC Inhibitor Resminostat in Combination Treatment with Sorafenib in Patients with Hepatocellular Carcinoma - The Phase I/II SHELTER study |
14.-17. Juni 2012
17th Congress of the European Hematology Association (EHA) in Amsterdam, The Netherlands |
|
Efficient HDAC inhibition and TARC reduction in patients with refractory Hodgkin’s lymphoma treated with Resminostat. PK/PD data from the Phase II SAPHIRE study |
1.-5. Juni 2012
2012 Annual Meeting of the American Society of Clinical Oncology (ASCO) in Chicago (USA) |
|
Efficacy, safety, tolerability and PK of the HDAC inhibitor resminostat in sorafenib-refractory hepatocellular carcinoma (HCC): Phase II SHELTER study
Press Release |
19.-21. Januar 2012
2012 Gastrointestinal Cancer Symposium (ASCO, ASTRO, SSO), San Francisco, USA |
|
Investigation of the HDAC Inhibitor Resminostat in Patients with Sorafenib-Resistant Hepatocellular Carcinoma (HCC): Clinical Data from the Phase I/II SHELTER Study |
10.-13. Dezember 2011
ASH - Jahrestagung der American Society of Hematology (ASH) in San Diego, USA |
|
Results of the Phase II SAPHIRE Trial of Resminostat (4SC-201) in Patients with Relapsed/Refractory Hodgkin Lymphoma |
7.-8. Dezember 2011
2nd World Epigentic Summit, München, Deutschland |
|
Resminostat: A Novel Oral Histone Deacetylase Inhibitor in Phase II Clinical Development |
22.-25. Juni 2011
ESMO 13th World Congress on Gastrointestinal Cancer, Barcelona, Spanien |
|
Clinical Update of the SHELTER Study: A Phase I/II Trial of HDAC Inhibitor Resminostat in Patients with Sorafenib-Resistant Hepatocellular Carcinoma (HCC)
A Phase I/II Study of Resminostat, an Oral Histone Deacetylase Inhibitor (HDACi), in Combination with FOLFIRI as Second-Line Treatment in KRAS Mutated Colorectal Cancer (CRC) patients - the SHORE Study |
20.-21. Januar 2011
2011 Gastrointestinal Cancer Symposium (ASCO, ASTRO, SSO), San Francisco, USA |
|
Clinical Update of the SHELTER Study: A Phase I/II Trial of HDAC Inhibitor Resminostat in Patients with Sorafenib-Resistant Hepatocellular Carcinoma (HCC) |
4.-7. Dezember 2010
ASH, Orlando, USA |
|
Resminostat in Relapsed or Refractory Hodgkin Lymphoma: Initial Results of the SAPHIRE Phase II Trial with a Novel Oral Histone Deacetylase (HDAC) inhibitor |
16.-19. November 2010
22nd EORTC-NCI-AACR Symposium, Berlin |
|
Clinical Phase II Development of Resminostat, a Novel HDAC Inhibitor
Centralised Analysis of Phase I ECG Dataset of Resminostat, a New Oral Histone Deacetylase Inhibitor (HDACi) |
23.-26. Oktober 2010
International Symposium on Hodgkin Lymphoma, Köln |
|
Initial Results from the SAPHIRE Study: A Phase II Trial with the Novel Oral Histone Deacetylase (HDAC) Inhibitor Resminostat in Relapsed or Refractory Hodgkin Lymphoma Patients |
17. September 2010
“Viszeralmedizin 2010” Symposium, Stuttgart |
|
First clinical data of resminostat, a novel oral histone deacetylase (HDAC) inhibitor, in patients with hepatocellular carcinoma (HCC) - the SHELTER study |
2010
Br J Haematol. 2010 May;149(4):518-28 |
|
The novel inhibitor of histone deacetylase resminostat (RAS2410) inhibits proliferation and induces apoptosis in multiple myeloma (MM) cells. |
29. Mai - 2. Juni 2009
ASCO, Orlando, Florida, USA |
|
A first-in-human Phase I study of 4SC-201, an oral histone deacetylase (HDAC) inhibitor, in patients with solid tumors |
